Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a challenging illness in neonatology. Higher than physiological oxygen levels impede the development of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue the normal retinal vasculature, and each has significant safety concerns. The limitations of these approaches have led to new efforts to understand the pathological characteristics in each phase of ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and with the need for new treatments for ROP, this review discusses the possible future use of unique populations of proangiogenic cells for therapeutic revascularization of the preterm retina.
CITATION STYLE
Trinh, T. L. P., Calzi, S. L., Shaw, L. C., Yoder, M. C., & Grant, M. B. (2016, May 26). Promoting vascular repair in the retina: Can stem/progenitor cells help? Eye and Brain. Dove Medical Press Ltd. https://doi.org/10.2147/EB.S94451
Mendeley helps you to discover research relevant for your work.